Key Updates From the CELESTIAL Trial Presented at ASH 2024

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.

The CAPTIVATE trial reveals long-term survival benefits of fixed-dose ibrutinib plus venetoclax for chronic lymphocytic leukemia patients, including high-risk groups.